Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy — CIDP  

Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy Clinical Trial

Official title: Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Status Completed

Clinical Trial Summary

Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy

Clinical Trial Description

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy ("ProCID trial") ;

Related Conditions & MeSH terms

• Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
• Peripheral Nervous System Diseases

• NCT number: NCT02638207
• Study type: Interventional
• Source: Octapharma
• Status: Completed
• Phase: Phase 3
• Start date: September 27, 2017
• Completion date: September 5, 2019